NZ603672A - Process for preparing pyrimidinone compounds - Google Patents

Process for preparing pyrimidinone compounds

Info

Publication number
NZ603672A
NZ603672A NZ60367211A NZ60367211A NZ603672A NZ 603672 A NZ603672 A NZ 603672A NZ 60367211 A NZ60367211 A NZ 60367211A NZ 60367211 A NZ60367211 A NZ 60367211A NZ 603672 A NZ603672 A NZ 603672A
Authority
NZ
New Zealand
Prior art keywords
formula
compound
treating
thio
heating
Prior art date
Application number
NZ60367211A
Other languages
English (en)
Inventor
Suzanne Helen Davies
Claire Frances Crawford
Kevin Stuart Cardwell
Charles Edward Wade
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ603672(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NZ603672A publication Critical patent/NZ603672A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NZ60367211A 2010-05-17 2011-05-17 Process for preparing pyrimidinone compounds NZ603672A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34522410P 2010-05-17 2010-05-17
PCT/US2011/036821 WO2011146494A1 (en) 2010-05-17 2011-05-17 Novel processes

Publications (1)

Publication Number Publication Date
NZ603672A true NZ603672A (en) 2015-01-30

Family

ID=44992024

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ60367211A NZ603672A (en) 2010-05-17 2011-05-17 Process for preparing pyrimidinone compounds

Country Status (25)

Country Link
US (2) US9447052B2 (enExample)
EP (1) EP2571857B1 (enExample)
JP (1) JP6027529B2 (enExample)
KR (1) KR20130089157A (enExample)
CN (2) CN105837520A (enExample)
AR (1) AR081399A1 (enExample)
AU (1) AU2011256270B2 (enExample)
BR (1) BR112012030532A2 (enExample)
CA (1) CA2799520C (enExample)
CL (1) CL2012003206A1 (enExample)
CO (1) CO6630197A2 (enExample)
CR (1) CR20120630A (enExample)
DO (1) DOP2012000289A (enExample)
EA (1) EA026569B1 (enExample)
IL (1) IL223068A0 (enExample)
MA (1) MA34301B1 (enExample)
MX (1) MX2012013387A (enExample)
NZ (1) NZ603672A (enExample)
PE (1) PE20130318A1 (enExample)
PH (1) PH12012502247A1 (enExample)
SG (1) SG185559A1 (enExample)
TW (1) TW201209043A (enExample)
UY (1) UY33388A (enExample)
WO (1) WO2011146494A1 (enExample)
ZA (1) ZA201208631B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201209043A (en) * 2010-05-17 2012-03-01 Glaxo Group Ltd Novel processes
WO2015087239A1 (en) 2013-12-11 2015-06-18 Ranbaxy Laboratories Limited Processes for the preparation of darapladib and its intermediates
WO2015092687A2 (en) 2013-12-17 2015-06-25 Ranbaxy Laboratories Limited Process for the purification of darapladib
ES2907130T3 (es) 2017-09-26 2022-04-22 Inst Nat Sante Rech Med Darapladib radiomarcado, análogos del mismo y su uso como compuestos para la obtención de imágenes
US10866963B2 (en) * 2017-12-28 2020-12-15 Dropbox, Inc. File system authentication
CN118221687B (zh) 2023-07-17 2024-12-31 上海枢境生物科技有限公司 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1143516B (de) * 1961-04-27 1963-02-14 Bayer Ag Verfahren zur Herstellung von Peptiden
US4277465A (en) 1978-08-26 1981-07-07 Kyoto Yakuhin Kogyo Kabushiki Kaisha Adjuvant for promoting absorption of therapeutically active substances through the digestive tract
US4235776A (en) * 1979-03-15 1980-11-25 Eli Lilly And Company Tetrahydro-2H-benzo[c]pyrroles
DE2941597A1 (de) * 1979-10-13 1981-04-23 Basf Ag, 6700 Ludwigshafen Piperidinderivate von 4,5-dialkyl-3-hydroxy-pyrrol-2-carbonsaeureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
US4619941A (en) * 1984-11-19 1986-10-28 American Cyanamid Company N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane synthetase inhibitors and antihypertensive agents
WO1999024420A1 (en) 1997-11-06 1999-05-20 Smithkline Beecham Plc Pyrimidinone compounds and pharmaceutical compositions containing them
US6750228B1 (en) * 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
WO2000028328A1 (en) 1998-11-05 2000-05-18 Biocryst Pharmaceuticals, Inc. New cyclopentane and cyclopentene compounds and use for detecting influenza virus
DE60042286D1 (de) * 1999-05-01 2009-07-09 Smithkline Beecham Plc Pyrimidinon Verbindungen
DE60139429D1 (de) * 2000-02-16 2009-09-10 Smithkline Beecham Plc Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
GB0119795D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
TW201209043A (en) * 2010-05-17 2012-03-01 Glaxo Group Ltd Novel processes

Also Published As

Publication number Publication date
EP2571857A4 (en) 2013-11-20
EA026569B1 (ru) 2017-04-28
PE20130318A1 (es) 2013-04-11
IL223068A0 (en) 2013-02-03
CN105837520A (zh) 2016-08-10
CN103003249B (zh) 2016-04-27
SG185559A1 (en) 2012-12-28
MX2012013387A (es) 2012-12-10
TW201209043A (en) 2012-03-01
US20130060028A1 (en) 2013-03-07
CL2012003206A1 (es) 2013-01-25
US9447052B2 (en) 2016-09-20
KR20130089157A (ko) 2013-08-09
BR112012030532A2 (pt) 2015-09-29
EA201291235A1 (ru) 2013-04-30
AR081399A1 (es) 2012-08-29
WO2011146494A1 (en) 2011-11-24
MA34301B1 (fr) 2013-06-01
JP6027529B2 (ja) 2016-11-16
EP2571857B1 (en) 2017-08-23
US20160347720A1 (en) 2016-12-01
AU2011256270A1 (en) 2012-12-20
CO6630197A2 (es) 2013-03-01
CA2799520A1 (en) 2011-11-24
JP2013530948A (ja) 2013-08-01
UY33388A (es) 2011-12-01
CN103003249A (zh) 2013-03-27
EP2571857A1 (en) 2013-03-27
US9725420B2 (en) 2017-08-08
PH12012502247A1 (en) 2013-02-04
CR20120630A (es) 2013-02-15
ZA201208631B (en) 2013-09-25
AU2011256270B2 (en) 2015-11-26
CA2799520C (en) 2016-09-13
DOP2012000289A (es) 2013-04-15

Similar Documents

Publication Publication Date Title
MY147440A (en) Process for making 3-substituted 2-amino-5-halobenzamides
TW200643014A (en) Chemical process
NZ598643A (en) Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs
CL2016000346A1 (es) Proceso para preparar compuestos intermediarios en la preparación de pirazolil pirrol pirimidinas.
WO2008009963A3 (en) Pyrimidine derivatives as modulators of parathyroid hormone receptors
AR073073A1 (es) Compuestos de pirrolo [ 2,3-d] pirimidina.
DK2057126T3 (da) Fremgangsmåde til fremstilling af 3-dihalomethyl-pyrazol-4-carboxylsyrederivater
WO2010125216A3 (es) Preparación de compuestos 5,6-dihidropirido[2,3-d]pirimidin-7(8h)-ona sustituidos
MXPA05008183A (es) Proceso para preparar pirrolotriazina como inhibidores de cinasa.
MX347955B (es) Novedoso anticuerpo anti-receptor de il-23 humano.
UA107344C2 (uk) Спосіб одержання 5-(2-{[6-(2,2-дифтор-2-фенілетокси)гексил]аміно}-1-гідроксіетил)-8-гідроксихінолін-2(1h)-ону
JP2013530948A5 (enExample)
MX354014B (es) Amidas de compuestos de 2-amino-4-ariltiazol y sus sales.
GEP20105099B (en) Method for preparation of optionally 2-substituted 1,6- dihydrocarboxil acids
WO2012087888A3 (en) Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (g) quinazoline trisodium salt
AR081399A1 (es) Proceso para preparar un compuesto de pirimidinona, compuestos intermediarios en dicho proceso y procesos para repararlos.
EA201200594A1 (ru) Способ получения 2-[(3,5-дифтор-3'-метокси-1,1'-бифенил-4-ил)амино]никотиновой кислоты
ATE553098T1 (de) Verfahren zur herstellung von rosuvastatin- calcium
TN2012000361A1 (en) Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
NZ611072A (en) Method for preparing rosuvastatin salts
UA93860C2 (ru) Способ получения пиразолов, способ региоселективного алкилирования и применение фосфата или фосфоната b способе
EA201300100A3 (ru) Способ ферментативного синтеза(7s)-3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-карбоновой кислоты или ее сложных эфиров, и применение для синтеза ивабрадина и его соли
WO2010115950A3 (en) Process for the preparation of pyrimidine derivatives
WO2011048612A3 (en) Process for preparation of propargylated aminoindans or pharmaceutically acceptable salts thereof
EA201291289A1 (ru) Кристаллическое производное тиенопиримидина

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 MAY 2016 BY AJ PARK

Effective date: 20150826

LAPS Patent lapsed